Context Therapeutics (CNTX) Corporate presentation summary

Strategic focus and pipeline overview

• Advancing a pipeline of T cell engagers (TCEs) targeting solid tumors with high unmet need, leveraging clinically validated tumor antigens and aiming for best-in-class selectivity and efficacy.

• Three lead bispecific antibody programs: CTIM-76 (CLDN6 x CD3), CT-95 (MSLN x CD3), and CT-202 (Nectin-4 x CD3), each designed for high selectivity and safety.

• Addressable U.S. patient populations exceed 50,000 for CLDN6, 100,000 for MSLN, and 125,000 for Nectin-4 annually in the relapsed/refractory setting.

• Strong financial position with cash runway projected into mid-2027.

CTIM-76 (CLDN6 x CD3) program highlights

• CLDN6 is an oncofetal protein overexpressed in ovarian, endometrial, lung, and testicular cancers, with minimal expression in adult tissues, making it an attractive immunotherapy target.

• Phase 1a data show 29% confirmed overall response rate (ORR) and 57% disease control rate (DCR) in heavily pretreated platinum-resistant ovarian cancer (PROC) patients, with low rates of cytokine release syndrome (CRS).

• Safety profile is favorable, with most adverse events being low grade and reversible; no dose reductions or discontinuations due to toxicity.

• Pharmacokinetic modeling suggests that less frequent dosing (every three weeks) may further improve durability and reduce T cell exhaustion.

• FDA Fast Track Designation granted; ongoing and planned studies include dose optimization and expansion into additional indications.

CT-95 (MSLN x CD3) program highlights

• MSLN is highly expressed in multiple solid tumors, including lung, pancreatic, ovarian, and mesothelioma, with a U.S. addressable population over 100,000 annually.

• CT-95 is engineered to bind membrane-bound MSLN, overcoming the challenge of shed mesothelin fragments that can limit efficacy of other agents.

• Preclinical data show high cytotoxicity even in the presence of soluble MSLN, differentiating it from competitors.

• Phase 1a/b study is ongoing, with preliminary data expected in September 2026.